News & Investors

Want to stay updated? Subscribe to our newsletters. For free.

Have questions? Our live support would be happy to help you.

Category: Press Releases

Epigenomics AG: Executive Board and Supervisory Board recommend acceptance of the voluntary public takeover offer

PDF Berlin, 14 June 2017 – The Executive Board and Supervisory Board of Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY) have evaluated the voluntary public takeover offer of Summit Hero Holding GmbH (“Bidder”) and have published their statement pursuant to section 27 of the German Takeover Act (Wertpapiererwerbs- und Übernahmeangebot ‑ WpÜG). The Executive Board […]

Read more

Offer document published for the voluntary public takeover offer for Epigenomics AG

PDF Berlin, 8 June 2017 – Today Summit Hero Holding GmbH published the offer document for the voluntary takeover offer for all outstanding shares of Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY). This marks the beginning of the acceptance period, in which Epigenomics shareholders can accept the cash offer of 7.52 Euros per share. […]

Read more

Epigenomics’ Annual General Meeting: CEO touts takeover offer

· Takeover offer is in the best interests of Epigenomics and its shareholders · Shareholders approved all agenda items according to the Board’s proposal   Berlin, 31 May 2017 – The speech from Greg Hamilton, CEO of Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY), at yesterday’s Annual General Meeting in Berlin focused primarily on […]

Read more

Epigenomics AG announces 2017 First Quarter Financial Results

Berlin (Germany) and Germantown, MD (U.S.A.), May 10, 2017 – Epigenomics AG (FSE: ECX, OTCQX: EPGNY), or the “Company”, today announced its financial results for the first quarter 2017 ended March 31. Q1/2017 Financial results Total revenue slightly decreased to EUR 281 thousand (Q1 2016: EUR 295 thousand) mainly due to the termination of a […]

Read more

Epigenomics AG Reports Results for Financial Year 2016

PDF Berlin (Germany) and Germantown, MD (U.S.A.), April 26, 2017 – Epigenomics AG (FSE: ECX, OTCQX: EPGNY), or the “Company”, today announced its financial results for the year ended December 31, 2016. Financial results ·     In 2016, Epigenomics’ total revenue increased by 102% to EUR 4.2 million (2015: EUR 2.1 million), exceeding previous year’s figure […]

Read more

Blitz F16-83 GmbH to launch takeover offer for Epigenomics AG

PDF Shareholders will be offered 7.52 Euros in cash per share valuing Epigenomics at approximately 171 million Euros The offer reflects a 49.4% premium to 3-month volume weighted average share price prior to announcement and a 32.0% premium to the highest closing price in the last 12 months Voluntary public takeover offer will be for […]

Read more
...